Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 9/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922528 | 0.98 | FDFT1 (0.54) | FDFT1CYP4F2CYP4A11TSHRHSD17B10 | |
| SCHEMBL7774935 | 0.95 | CYP4F2 (0.56) | FDFT1CYP4F2CYP4A11TSHRHSD17B10 | |
| SCHEMBL2347947 | 0.87 | CYP4F2 (0.69) | FDFT1CYP4F2CYP4A11TSHRHSD17B10 | |
| SCHEMBL23720120 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11FFAR1 | |
| SCHEMBL5760533 | 0.83 | CYP4F2 (0.79) | CYP4F2CYP4A11TSHRFFAR1 | |
| SCHEMBL30940733 | 0.83 | ADRB2 (0.51) | FDFT1CYP4F2CYP4A11TSHRHSD17B10 | |
| SCHEMBL25047484 | 0.83 | ADRB2 (0.51) | FDFT1CYP4F2CYP4A11TSHRHSD17B10 | |
| SCHEMBL7653722 | 0.83 | FDFT1 (0.52) | FDFT1FFAR1 | |
| SCHEMBL10106193 | 0.83 | PPARA (0.60) | FDFT1 | |
| SCHEMBL416922 | 0.83 | MAOA (0.60) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1709851-A | Clean production method for fenoprofen calcium | NANTONG HUAFENG CHEMICAL LLC (CN) | 2005-12-21 | — | — | CN | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |